X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare J.B.Chemicals with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs PIRAMAL ENTERPRISES - Comparison Results

J.B.CHEMICALS    Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS PIRAMAL ENTERPRISES J.B.CHEMICALS/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 18.1 10.9 165.4% View Chart
P/BV x 2.5 1.9 130.0% View Chart
Dividend Yield % 0.2 0.9 18.3%  

Financials

 J.B.CHEMICALS   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-16
PIRAMAL ENTERPRISES
Mar-18
J.B.CHEMICALS/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3183,083 10.3%   
Low Rs2001,902 10.5%   
Sales per share (Unadj.) Rs148.0589.7 25.1%  
Earnings per share (Unadj.) Rs19.1284.0 6.7%  
Cash flow per share (Unadj.) Rs23.9310.5 7.7%  
Dividends per share (Unadj.) Rs0.5025.00 2.0%  
Dividend yield (eoy) %0.21.0 19.3%  
Book value per share (Unadj.) Rs128.91,467.0 8.8%  
Shares outstanding (eoy) m84.82180.27 47.1%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.74.2 41.4%   
Avg P/E ratio x13.68.8 154.5%  
P/CF ratio (eoy) x10.88.0 134.6%  
Price / Book Value ratio x2.01.7 118.1%  
Dividend payout %2.68.8 29.8%   
Avg Mkt Cap Rs m21,951449,332 4.9%   
No. of employees `0002.76.8 40.0%   
Total wages/salary Rs m1,84119,881 9.3%   
Avg. sales/employee Rs Th4,590.915,535.6 29.6%   
Avg. wages/employee Rs Th673.42,905.4 23.2%   
Avg. net profit/employee Rs Th592.17,482.5 7.9%   
INCOME DATA
Net Sales Rs m12,551106,310 11.8%  
Other income Rs m5422,595 20.9%   
Total revenues Rs m13,093108,906 12.0%   
Gross profit Rs m2,05551,599 4.0%  
Depreciation Rs m4124,773 8.6%   
Interest Rs m9629,783 0.3%   
Profit before tax Rs m2,08819,638 10.6%   
Minority Interest Rs m02,801 -0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m469-28,764 -1.6%   
Profit after tax Rs m1,61951,203 3.2%  
Gross profit margin %16.448.5 33.7%  
Effective tax rate %22.5-146.5 -15.3%   
Net profit margin %12.948.2 26.8%  
BALANCE SHEET DATA
Current assets Rs m7,778118,154 6.6%   
Current liabilities Rs m4,358462,260 0.9%   
Net working cap to sales %27.2-323.7 -8.4%  
Current ratio x1.80.3 698.2%  
Inventory Days Days5527 205.7%  
Debtors Days Days8047 172.0%  
Net fixed assets Rs m5,713113,727 5.0%   
Share capital Rs m170361 47.0%   
"Free" reserves Rs m10,547264,093 4.0%   
Net worth Rs m10,937264,454 4.1%   
Long term debt Rs m0242,206 0.0%   
Total assets Rs m15,574726,834 2.1%  
Interest coverage x22.81.7 1,375.2%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.80.1 551.0%   
Return on assets %11.011.1 98.8%  
Return on equity %14.819.4 76.4%  
Return on capital %20.010.3 193.7%  
Exports to sales %48.70-   
Imports to sales %7.10-   
Exports (fob) Rs m6,115NA-   
Imports (cif) Rs m889NA-   
Fx inflow Rs m6,16915,110 40.8%   
Fx outflow Rs m1,2854,298 29.9%   
Net fx Rs m4,88410,813 45.2%   
CASH FLOW
From Operations Rs m1,397-159,666 -0.9%  
From Investments Rs m-320-17,677 1.8%  
From Financial Activity Rs m-1,196186,503 -0.6%  
Net Cashflow Rs m-1029,364 -1.1%  

Share Holding

Indian Promoters % 55.4 52.9 104.7%  
Foreign collaborators % 0.3 0.0 -  
Indian inst/Mut Fund % 3.4 4.0 84.8%  
FIIs % 3.9 26.6 14.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 16.5 224.2%  
Shareholders   30,437 93,274 32.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  TTK HEALTHCARE  MERCK LTD  

Compare J.B.CHEMICALS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Sep 19, 2018 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS 8-QTR ANALYSIS

COMPARE J.B.CHEMICALS WITH

MARKET STATS